(E)-N-(4-(2-(3-bromo-4-hydroxy-5-methoxybenzylidene)hydrazinecarbonyl)phenyl)pentanamide

ID: ALA3394895

PubChem CID: 136001911

Max Phase: Preclinical

Molecular Formula: C20H22BrN3O4

Molecular Weight: 448.32

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCC(=O)Nc1ccc(C(=O)N/N=C/c2cc(Br)c(O)c(OC)c2)cc1

Standard InChI:  InChI=1S/C20H22BrN3O4/c1-3-4-5-18(25)23-15-8-6-14(7-9-15)20(27)24-22-12-13-10-16(21)19(26)17(11-13)28-2/h6-12,26H,3-5H2,1-2H3,(H,23,25)(H,24,27)/b22-12+

Standard InChI Key:  JDYIARKCILFUMT-WSDLNYQXSA-N

Molfile:  

     RDKit          2D

 28 29  0  0  0  0  0  0  0  0999 V2000
    1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0031   -3.0008    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.0432   -3.5993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3383   -1.3500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3383    1.3500    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
    2.5972    1.5031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5951    3.0039    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8933    3.7570    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8912    5.2578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1894    6.0109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8509    5.8560    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.1894    7.5110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4884    8.2610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7875    7.5110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7875    6.0110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4885    5.2610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0888    8.2588    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3875    7.5066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6887    8.2544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3854    6.3066    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.9874    7.5021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2887    8.2499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3271    7.6485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  6  7  1  0
  7  8  1  0
  5  9  1  0
  4 10  1  0
  2 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 14 16  2  0
 15 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 15  1  0
 19 22  1  0
 22 23  1  0
 23 24  1  0
 23 25  2  0
 26 24  1  0
 26 27  1  0
 27 28  1  0
M  END

Alternative Forms

  1. Parent:

    ALA3394895

    ---

Associated Targets(Human)

ASF1A Tchem Histone chaperone ASF1A (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 448.32Molecular Weight (Monoisotopic): 447.0794AlogP: 4.06#Rotatable Bonds: 8
Polar Surface Area: 100.02Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 8.29CX Basic pKa: 0.88CX LogP: 4.10CX LogD: 4.05
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.42Np Likeness Score: -1.21

References

1. Miknis GF, Stevens SJ, Smith LE, Ostrov DA, Churchill ME..  (2015)  Development of novel Asf1-H3/H4 inhibitors.,  25  (4): [PMID:25582598] [10.1016/j.bmcl.2014.11.067]
2. Miknis, Greg F; Stevens, Sarah J; Smith, Luke E; Ostrov, David A and Churchill, Mair E A.  2015-02-15  Development of novel Asf1-H3/H4 inhibitors.  [PMID:25582598]

Source